Amirah M M Alatawi

Dr. Amirah M M Alatawi

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2022 in Cureus
Verified
Journal Article
Open access
MAMansuor A. Alanazi
Mansuor A. Alanazi
AAAmirah M M Alatawi
Amirah M M Alatawi
Diabetes Mellitus (DM) types 1 and 2 and their complications are becoming more prevalent in Saudi Arabia. Non-adherence to diabetes management techniques could result in inadequate blood sugar management causing treatment failure, the rapid development of comorbidities, and higher mortality in patients with diabetes. This study investigated the adherence of patients with diabetes in the Tabuk region of Saudi Arabia to their prescribed medications and examined the association between adherence and other sociodemographic characteristics. This cross-sectional study was conducted in Tabuk, Saudi Arabia, among patients with diabetes. A validated online self-administered questionnaire was provided to the research participants using Google Forms. Participants were selected using a convenient non-probability sampling method. The chi-square test was used to compare qualitative data whereas quantitative data were expressed as frequency and percentage. Overall, 380 participants were enrolled in this study. The study population’s average diabetes treatment adherence score was 9.6 ± 3.3% from a maximum score of 15 (range: 0-15). Overall, 293 (77.1%) participants were adherent, whereas 87 (22.9%) were non-adherent. In addition, more than one-third of the individuals did not miss medication doses or follow-up appointments. However, forgetfulness was the most common cause of missed medicine doses and follow-up appointments. In addition, several sociodemographic characteristics, including marital status, nationality, geographic region, and employment position, were significantly associated with DM treatment adherence (P = 0.001, 0.002, 0.003, and 0.002, respectively). Most individuals in Tabuk, Saudi Arabia, showed adequate DM medication adherence. Forgetfulness was the most common cause for missed medicine doses and follow-up appointments while several socioeconomic factors including marital status, nationality, geographic region, and occupation were associated with treatment adherence. Therefore, intervention strategies and public health campaigns should be implemented to increase treatment adherence among patients with DM.

28 June 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Helal HettaHelal Hetta
Helal Hetta
MAMostafa Ali
Mostafa Ali
SASaleh F Alqifari
Saleh F Alqifari
HSHoda Abdelaziz Salem
Hoda Abdelaziz Salem
KQKhulood A. Qasem
Khulood A. Qasem
Reem SayadReem Sayad
Reem Sayad
Background/Objectives: Non-small-cell lung cancer (NSCLC) frequently metastasizes to the brain, significantly impacting patient prognosis and quality of life. Anlotinib, a novel tyrosine kinase inhibitor, has shown promise in treating NSCLC with brain metastasis. So, we aimed to evaluate the clinical efficacy of anlotinib and various types of radiotherapy combinations used to treat NSCLC patients with brain metastasis regarding overall survival and the treatment of internal and external lesions. Methods: A comprehensive literature search was conducted in the databases PubMed, Scopus, WoS, MedLine, and Cochrane Library up to April 2024. Studies assessing the efficacy of anlotinib combined with whole-brain radiotherapy (WBRT), stereotactic radiosurgery (SRS), or other radiotherapy modalities in NSCLC patients with brain metastasis were included. The primary outcomes were (a) the efficacy of anlotinib and radiotherapy on the intracranial lesions and OS and (b) the effectiveness of combined anlotinib and radiotherapy versus radiotherapy alone in NSCLC patients with brain metastasis. The secondary outcome was the efficacy of anlotinib and radiotherapy on extracranial progression. We used a combination of keywords and MeSH terms including ‘non-small cell lung cancer’ OR ‘NSCLC’, ‘brain metastases’, ‘anlotinib’, ‘radiotherapy’, ‘radiation therapy’, and ‘combined treatment’, among others. Boolean operators (AND, OR) were applied as appropriate to optimize the search strategy across databases. Results: Nine studies met the inclusion criteria, comprising 210 patients in the combination group and 228 patients in the radiotherapy alone group. The combination of anlotinib with radiotherapy showed a significant improvement in iPFS compared to radiotherapy alone, with a pooled risk ratio (RR) for iORR of 1.18 (95% CI: 1.00–1.39) and a pooled SMD for OS of 0.03 (95% CI: −0.29, 0.36). Radiotherapy combined with anlotinib also demonstrated enhanced intracranial and extracranial control rates. Conclusions: Anlotinib combined with radiotherapy, especially WBRT, offers a promising treatment strategy for NSCLC patients with brain metastasis, improving intracranial control. Further large-scale randomized controlled trials are needed to confirm these findings and optimize treatment protocols.

17 February 2023 in Cureus
Verified
Journal Article
Open access
PDF file
AAAmirah M M Alatawi
Amirah M M Alatawi
HMHassan A Moria
Hassan A Moria
AAAbdulrahman Arshed Alharfy
Abdulrahman Arshed Alharfy
MSMohammed Jameel Sehly
Mohammed Jameel Sehly
JAJalawi Talal A Alotaibi
Jalawi Talal A Alotaibi
ASAbdulrahman Jameel Sehly
Abdulrahman Jameel Sehly
Background: Adequately informed family physicians have the greatest potential to correctly identify the diagnosis of fibromyalgia (FM) and develop an initial treatment plan. Therefore, it is substantial to determine the levels of weakness and inaccuracy among primary care physicians regarding FM diagnostic criteria and management strategies. Aim: This study aimed to assess the knowledge, attitude, and practices regarding FM among primary care physicians in Tabuk, Saudi Arabia. Methods: This cross-sectional study included family physicians who were board-certified or registered in the family medicine training program and working at the government family healthcare centers in Tabuk. A pre-designed, structured questionnaire was distributed either in written form or as an online survey. Results: This study included 52 primary healthcare physicians. Twenty-two (42.3%) participants incorrectly recorded localized pain as a diagnostic symptom, and 45 (86.5%) incorrectly recorded nonsteroidal anti-inflammatory drugs (NSAIDs), prednisolone, and/or opioids as drugs that are used for treating FM. Only 59.6% were confident in recognizing the symptoms of FM, and 55.8% were confident in differentiating FM from other similar diseases. Conclusions: The primary healthcare physicians working in the government’s primary healthcare centers in Tabuk City, Saudi Arabia, have low levels of knowledge about diagnostic criteria and treatment strategies for FM. These findings highlight the need for continuous professional development involving family physicians in the primary healthcare setting with suitable continuous medical education (CME) programs concerning FM.

5 December 2025 in Medicine
Verified
Journal Article
Open access
AAAmal Omar Alansari
Amal Omar Alansari
AAAhlam Saleem Alharbi
Ahlam Saleem Alharbi
KAKhaled Mohammad Alshehri
Khaled Mohammad Alshehri
AAAli Tareq Alhabib
Ali Tareq Alhabib
BABodour Saleh Alsalmi
Bodour Saleh Alsalmi
AAAmirah M M Alatawi
Amirah M M Alatawi
Background: Glucagon-like peptide-1 receptor agonists (GLP-1 agonist) have revolutionized the treatment of obesity. However, regulatory agencies have reported an association with suicidality. To the best of our knowledge, this is the first meta-analysis to assess the association between GLP-1 agonist use, suicidal ideation, and suicide completion. We aimed to assess the same in patients with diabetes and obesity. Methods: We searched 6 databases for relevant articles, from the first published article to October 2024. The keywords used were GLP-1 agonists, suicidal ideation, suicide, suicidal behavior, semaglutide, liraglutide, tripeptide, exenatide, and lixisenatide. We identified 354 studies and 126 stands after the removal of duplicates, of which 23 were eligible, and only 12 studies were included in the final meta-analysis. Results: No significant statistical difference was found in suicidal ideations in patients on GLP-1 agonists compared to their counterparts on other obesity and diabetes drugs (odds ratio [OR], 1.0; 95% confidence interval [CI]: 1.0–1.0). No significant difference was observed between patients on GLP-1 agonists and their counterparts regarding complete suicide (OR, 1.77; 95% CI: 0.80–3.91). In a subgroup analysis, suicide was higher among patients on liraglutide compared to their counterparts on semaglutide (OR, 1.48; 95% CI: 1.17–1.89). No significant statistical difference was observed when comparing monjaro and semaglutide (OR, 0.98; 95% CI: 0.94–1.03). Conclusion: No significant statistical difference was found between GLP-1 agonists and other obesity and diabetes drugs regarding suicide/suicidal ideation. In a subgroup analysis, suicide was higher in patients on liraglutide compared to semaglutide, with no significant difference between semaglutide and monjaro. Randomized controlled trials that assess the association between GLP-1 agonists and suicidality are highly recommended.

22 November 2024 in Frontiers in Endocrinology
Verified
Journal Article
Open access
PDF file
AAAmirah M M Alatawi
Amirah M M Alatawi
MAMansuor A. Alanazi
Mansuor A. Alanazi
MAMaram Ati Almohammadi
Maram Ati Almohammadi
Background: Obesity is one of the most prevalent and relevant health problems in Saudi Arabia and requires urgent attention. Family physicians are the first point of contact and one of the most important starting points for the successful treatment of being overweight or obese.Aim: This study aimed to assess the knowledge, beliefs, and practices of primary care physicians in promoting healthy lifestyles and physical activity among obese patients.Methods: This cross-sectional study included family physicians who were board-certified or registered in a family medicine training program and working at government family healthcare centers in Tabuk. A predesigned structured questionnaire was distributed either in a printed form or as an online survey.Results: The study included 83 family physicians. Of these, 84.1% agreed that overweight and obese patients should be screened for dyslipidemia, and 67.5% agreed to offer advice on weight control even if the patient did not ask for it, demonstrating what family medicine physicians thought of physical inactivity (97.6%). Assessment of the obesity counseling practices of family medicine physicians revealed that approximately three-fourths (75.9%) always calculated the body mass index (BMI) of patients during obesity management, while comprehensive counseling regarding physical activity was higher (81.9%). The system for providing educational materials as part of managing overweight or obesity was found to be inadequate as 25.3% had never done so. The family medicine physicians had sufficient knowledge and positive beliefs about obesity management but also improper counseling practices. A lack of training and poor patient compliance with management plans are the main barriers to controlling obesity levels.

16 January 2026 in Medicine
Verified
Journal Article
Open access
HAHisham Alshadfan
Hisham Alshadfan
HMHyder Mirghani
Hyder Mirghani
TATariq Alrasheed
Tariq Alrasheed
MAMansuor A. Alanazi
Mansuor A. Alanazi
AAAmirah M M Alatawi
Amirah M M Alatawi
MAMuhammad Nazrul Hakim Abdullah
Muhammad Nazrul Hakim Abdullah
Gastrointestinal (GI) side effects from metformin often limit its use and can impact patient quality of life (QoL) and satisfaction. The extended-release (XR) formulation is thought to cause fewer GI adverse events than immediate-release (IR) metformin, potentially improving tolerability, treatment satisfaction, and adherence. To compare metformin IR vs XR in terms of GI tolerability (incidence of GI side effects), patient-reported QoL, and medication satisfaction over 6 months in Saudi patients with type 2 diabetes. In a prospective cohort of 119 newly diagnosed patients with type 2 diabetes (62 on IR, 57 on XR), we tracked GI adverse events using a standardized questionnaire at baseline and 6-month follow-up. Diabetes-specific QoL was measured with the diabetes therapy-related quality of life questionnaire (DTR-QOL), and treatment satisfaction was assessed with the oral hypoglycemic agent questionnaire version 2 (OHA-Q ver. 2). Metformin XR was associated with significantly better GI tolerability. By 6 months, 45.2% of IR patients and only 24.5% of XR patients reported any GI side effect ( P <.05). Rates of bothersome symptoms, such as diarrhea, were notably higher in the IR group. Patients on XR reported fewer interruptions of therapy due to GI upset. The DTR-QOL global score improved in both groups ( P <.05), but there was no significant difference in total DTR-QOL scores between groups ( P = .390). The OHA-Q ver. 2 global score improved in both groups ( P <.05), but the XR group had higher scores in domains related to satisfaction (median treatment satisfaction domain score 100 vs 77.78 for IR, P < .05), with a significant difference in OHA-Q ver. 2 global score (92.59 vs 86.31 for IR; P <.05). Metformin XR demonstrated superior GI tolerability, which translated into improved treatment satisfaction compared to IR. While the overall quality of life related to diabetes management improved similarly with both, the XR formulation reduced side effect burden, and the lower daily dosing led to higher patient-reported satisfaction. These findings support the use of metformin XR to enhance tolerability and adherence, potentially leading to improved long-term outcomes.